8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Bluefield Solar Income Fund Ltd(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDOX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree JTC PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

EssilorLuxottica to acquire Signifeye,further growing its ophthalmology clinics footprint Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and clinics in the Flanders region. The transaction comes soon after the recent acquisition of Optegra, a fast-growing and highly integrated ophthalmology platform in Europe operating over 70 clinics in the UK, Czech Republic, Poland, Slovakia and the Netherlands. While strengthening Optegra’s position in Europe, it also advances EssilorLuxottica’s med-tech trajectory and its ambition to pioneer the most advanced, integrated and expert-driven medical model, capable of addressing the full continuum of need, from prevention and early detection to specialized...

SAN JOSE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — In another step toward providing safe, reliable water to Palm Mutual Water company (Palm Mutual) customers long-term, California Water Service (Cal Water) has received California Public Utilities Commission (CPUC) approval of its pending acquisition of Palm Mutual. Cal Water is the largest subsidiary of California Water Service Group (NYSE: CWT). Palm Mutual, located two miles from Cal Water’s Northeast Bakersfield Treatment Plant, currently serves 63 residential customers. Cal Water already serves Palm Mutual through a master meter interconnection, since the latter does not own or operate its own sources of supply. Cal Water intends to upgrade the system’s infrastructure over time to help provide consistent and high-quality operations to Palm Mutual customers. “We appreciate the...

Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced a definitive agreement for Cycle Group Holdings Limited (“Cycle”) to acquire Applied Therapeutics. Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic...

Creating One of the Largest Omni-Channel Retailers Across the Full Inclusive Sizing Market, with Approximately $1.2 Billion of Combined Annual Net Sales Poised to Capture Accelerated Growth Opportunities in an Underserved, Fragmented Market Expect $25 Million in Annual Run-Rate Cost Synergies Significantly Actioned Within the First 12 Months of Closing, with Meaningful Commercial Synergy Upside Enhancing Financial Position and Free Cash Flow Generation, While Exercising Disciplined Capital Allocation to Drive Future Growth and Shareholder Returns Companies to Host a Joint Investor Conference Call at 5:00 PM U.S. Eastern Time CANTON, Mass. and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (“DXL”) (NASDAQ: DXLG), the leading integrated commerce retailer of Big + Tall men’s clothing and footwear, and FBB Holdings...

CAMPBELL, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP for accelerating semiconductor creation in the AI era, today announced it has entered into a definitive agreement to acquire Cycuity, Inc., a leading provider of semiconductor cybersecurity assurance. The addition of Cycuity’s technology and expertise strengthens Arteris’ product portfolio, enabling chip designers to understand and improve data movement security in chiplets and SoCs. This pending acquisition addresses a growing industry concern about the increasing volume of sophisticated cyberattacks targeting the vast amounts of unsecured data moving through semiconductors, from AI data centers to a broad range of edge devices. “In today’s world, where vast amounts of data are traversing every SoC and chiplet, the need...

GUADALAJARA, Mexico, Dec. 11, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“GAP”) announces that, during its Ordinary and Extraordinary General Shareholders’ Meeting, with a quorum of 88.1% of its shareholders, around 96% of the votes cast approved the business combination of the Cross Border Xpress (CBX) and the provision of technical assistance and technology transfer services. This business combination will be carried out through the merger of various entities into GAP, including, among others, Aeropuertos Mexicanos del Pacífico, S.A.P.I. de C.V. (AMP), our current strategic partner. Consequently, we expect to issue approximately 90 million net new shares and to acquire control of the merged entities, which will allow us to consolidate them. As of today, we have approximately...

SASKATOON, Saskatchewan, Dec. 11, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a non-binding letter of intent (“LOI”) to acquire from an arm’s length vendor (the “Vendor”) the prescription files, patient records, and related operational data (the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp’s existing PharmaChoice-bannered pharmacies in Western Canada (the “Proposed Acquisition”). The purchase price for the Proposed Acquisition is anticipated to be $350,000 subject to customary adjustments. The Proposed Acquisition will be satisfied with cash on hand with closing expected to occur during the first quarter of 2026. No finder’s fees are payable in respect of the Proposed Acquisition. The Proposed Acquisition...